Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: Radiother Oncol. 2023 Nov 14;190:110005. doi: 10.1016/j.radonc.2023.110005

Fig. 2.

Fig. 2.

Cumulative incidence of all-cause mortality, major adverse cardiac events (MACE), and grade ≥ 3 cardiac events (A) among all patients, (B) among patients with baseline coronary heart disease (CHD), and (C) among patients without baseline CHD. MACE and grade ≥ 3 cardiac events are adjusted for the competing risk of death.